News Amarin Corporation plc

Stocks

AMRN

US0231114044

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-28 EDT			5-day change	1st Jan Change
13.25 ^USD	+0.38%		-1.71%	-5.05%

09-25	European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week	MT
09-10	European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading	MT

All News

Mentions Relevance

08-31	Amarin Highlights New Reduce-It and Mechanistic Data At European Society of Cardiology Congress	CI
08-31	Amarin - New REDUCE-IT Legacy Analysis Presented at European Society of Cardiology Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients	AQ
08-31	Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026	AQ
08-28	New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients	AQ
08-24	New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026	AQ
07-29	Amarin Corporation plc, Q2 2026 Earnings Call, Jul 29, 2026
07-29	Tranche Update on Amarin Corporation plc's Equity Buyback Plan announced on May 1, 2024.	CI
07-29	Amarin Corporation plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-29	Amarin: Q2 Earnings Snapshot	AQ
07-29	Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence	AQ
07-15	Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026	AQ
06-30	Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	AQ
06-30	Amarin Corporation plc Reaffirms the Proven Guideline-Recommended Role of Vascepa (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape	CI
06-04	Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case	MT
06-04	Top cases on the US Supreme Court's docket	RE
06-04	Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case	MT
06-04	Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case	MT
05-27	New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia	AQ
05-27	Amarin Corporation plc Presents New REDUCE-IT Analysis At European Atherosclerosis Society Congress 2026	CI
05-01	US appeals court revives Amarin heart-drug patent lawsuit over Hikma generic - June 25, 2024	RE
04-29	Amarin Corporation plc, Q1 2026 Earnings Call, Apr 29, 2026
04-29	Amarin: Q1 Earnings Snapshot	AQ
04-29	Tranche Update on Amarin Corporation plc's Equity Buyback Plan announced on May 1, 2024.	CI
04-29	Amarin Corporation plc Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-29	Amarin Reports 2026 First Quarter Financial Results	AQ